ProCE Banner Activity

KEYNOTE-013: Pembrolizumab in Classical Hodgkin’s Lymphoma After Brentuximab Vedotin Failure

Slideset Download
Conference Coverage
In this early study, pembrolizumab was highly active with durable responses in heavily pretreated patients with cHL who had failed brentuximab vedotin.

Released: December 14, 2015

Expiration: December 12, 2016

No longer available for credit.

Share

Provided by

Jointly provided by the Annenberg Center for Health Sciences at Eisenhower and Clinical Care Options, LLC
ProCE Banner

Supporters

Amgen, Inc.

Celgene

Incyte

Merck & Co., Inc.

Millennium Takeda

Seagen